Abstract 323P
Background
Tumor mutation burden (TMB) may predict immune checkpoint inhibitor (ICI) response. TMB calculation included all nonsynonymous somatic mutations, but not all mutations were favorable and the efficient of TMB is attenuated by including adverse mutations. Moreover, no universal cutoff value of high TMB hindered its application in practice.
Methods
Tumor mutation score (TMS), defined as number of genes with nonsynonymous somatic mutations, was compared with TMB in 10,336 cancer patients from MSK-IMPACT cohort. TMS55, TMS of 55 favorable prognosis genes and TMB were calculated and compared in 1,661 advanced cancer patients treated with ICI and 3,840 matching non-ICI patients of ten major cancer types.
Results
TMS55 was significantly associated with TMB. In 1,661 ICI patients, high TMS55 (TMS55>5) was more robust than high TMB (highest 20% in each histology) in predicting better overall survival. Separately, TMS55 was significantly associated with improved survival in more tumor types than TMB with smaller hazard ratio values, especially in non-small cell lung cancer, melanoma, bladder cancer and colorectal cancer. Conversely, high TMS55 and TMB predicted worse overall survival in 3,840 non-ICI patients.
Conclusions
Novel TMS55 might be better than TMB as biomarker for patients treated with ICI and customized TMS might substitute non-selective TMB as mutation-based biomarker. Easy calculation and universal cutoff value of TMS will not be affected across platforms and is more feasible in clinical, which may greatly promote its application in clinical with further validations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
174P - Progression of computer aided diagnosis on gastric cancer
Presenter: Yingyan Yu
Session: Poster display session
Resources:
Abstract
175P - Hypermethylation of the PCDHB15 promoter predicts the prognosis in gastric cancer
Presenter: Yu-ting Lee
Session: Poster display session
Resources:
Abstract
176P - DCLK1 promotes tumour invasion and metastasis through epithelial-mesenchymal transition and the MEK/ERK pathway in esophageal squamous cell carcinoma
Presenter: Jiannan Yao
Session: Poster display session
Resources:
Abstract
177P - Comparison of nab-paclitaxel plus ramcirumab and paclitaxel plus ramcirumab in patients with pretreated metastatic gastric cancer
Presenter: Yosuke Horita
Session: Poster display session
Resources:
Abstract
178P - Chief cell in stomach have stem cell activity and potential to develop gastric cancer
Presenter: Akihiro Yamamura
Session: Poster display session
Resources:
Abstract
179P - Postoperative Adjuvant transarterial chemoembolization versus surgery alone for resected hepatocellular carcinoma: A propensity-score matching study
Presenter: Mingyu Chen
Session: Poster display session
Resources:
Abstract
180P - LHPP inhibit the cell proliferation and EMT via the TGFβ/SMAD3 signaling pathway in iCCA
Presenter: Dan Wang
Session: Poster display session
Resources:
Abstract
181P - The emerging role of third-line gemcitabine plus nab-paclitaxel in advanced pancreatic adenocarcinoma
Presenter: Andrew Dean
Session: Poster display session
Resources:
Abstract
182P - Durable response to second-line m-FOLFIRINOX for advanced pancreatic adenocarcinoma in patients with performance status of two or less
Presenter: Adarsh Das
Session: Poster display session
Resources:
Abstract
183P - Epidemiologic profile of gastric cancer in East Azerbaijan, Iran: 2 years population-based cancer registry results
Presenter: Pooneh Jabbaripour
Session: Poster display session
Resources:
Abstract